Semax: efficacy in experimental brain ischemia

Experimental study on Wistar rats showed that the use of Semax with global cerebral ischemia in animals has some positive effect, significantly reducing the severity of neurological deficit during the first 6.5 hours compared with those in the control group. The observed trend of increasing animal and prolongation of survival until the first death in the group may also be due to the neuroprotective properties of the drug.

In the study of the effects of Semax models of acute focal cerebral ischemia established increase animal survival after experimental stroke, a significant decrease in the frequency of bleeding complications and severity of neurological deficit.